Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
{{output}}
Background: First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E-mutated metastatic colorectal cancer, an aggressive subtype ... ...
